$26.830
-1.553 (-5.79%)At close
BDSX News
BDSX Events
Biodesix Files to Sell 375,000 Shares of Common Stock
Biodesix files to sell 375,000 shares of common stock for holders
Biodesix Expects FY26 Revenue of $108M to $114M
Consensus $108.68M. Backs FY26 gross margin view 80%. Still sees adjusted EBITDA continuing improvement on path to profitability. The company said, "For full year 2026, the Company expects total revenue of $108-114 million, with the midpoint representing approximately 25% growth over 2025. Biodesix expects continued progress toward achieving and maintaining Adjusted EBITDA profitability, driven by increasing sales productivity, expanded clinical evidence supporting the Nodify Lung tests, growth in the Development Services pipeline, and demonstrated operating leverage."
Biodesix Q1 Revenue at $22.29M, Below Consensus
Reports Q1 revenue $22.29M, consensus $23.18M. "Biodesix delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business," said Scott Hutton, Chief Executive Officer. "Test volumes grew 29%, Development Services revenue doubled, and average revenue per test increased through expanded payer coverage and improved revenue cycle management, driving total revenue growth of 42% year over year. We were also recognized as a Top Workplace for the third consecutive year, reinforcing that our culture is not aspirational, its operational. Our first quarter results reflect a disciplined culture of execution in service to our partners, healthcare providers, and the patients they serve. With strong performance across both business lines and continued operational leverage, we are raising our full-year 2026 guidance and remain on a clear path toward profitability."
Company Sees FY26 Gross Margin at 80%
Sees FY26 gross margin 80%. The company said, "The Company anticipates generating between $106-112 million in total revenue in 2026, the mid-point representing 23% growth over 2025 total revenue, and expects continued improvement toward sustained Adjusted EBITDA positivity. The revenue growth and improvement on the path to profitability is expected to be driven by the increasing productivity across our expanded sales organization, improvements to average revenue per test demonstrated in the second half of 2025, additional clinical data on the Nodify Lung tests to help drive adoption from healthcare providers and payers, increases in Development Services pipeline, and the demonstrated operating leverage."
Biodesix Reports Q4 Revenue of $28.76M
Reports Q4 revenue $28.76M, consensus $26.25M. "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, CEO. "We exceeded the high end of our revenue guidance by delivering 41% growth, and for the first time ever, achieved Adjusted EBITDA positivity in the quarter demonstrating the strength of our operating leverage and gross margins, which have become a hallmark of Biodesix performance. In 2025, we accelerated the growth of our lung-focused commercial strategy, expanded our pipeline, announced new partnerships, grew our development services offering, and presented clinical data on our on-market and pipeline products."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.